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Abstract: A second generation of 4-aminoquinoline- and 8-aminoquinoline-based tetrazoles and
lactams were synthesized via the Staudinger and Ugi multicomponent reactions. These compounds
were subsequently evaluated in vitro for their potential antiplasmodium activity against a
multidrug-resistant K1 strain and for their antitrypanosomal activity against a cultured T. b. rhodesiense
STIB900 strain. Several of these compounds (4a–g) displayed good antiplasmodium activities
(IC50 = 0.20–0.62 µM) that were comparable to the reference drugs, while their antitrypanosomal
activity was moderate (<20 µM). Compound 4e was 2-fold more active than primaquine and was
also the most active (IC50 = 7.01 µM) against T. b. rhodesiense and also exhibited excellent aqueous
solubility (>200 µM) at pH 7.
Keywords: human African trypanosomiasis (HAT); Plasmodium falciparum chloroquine
multidrug-resistant (K1) strain; 4-aminoquinoline β-lactams; 8-aminoquinoline tetrazoles; aqueous
kinetic solubility
1. Introduction
Neglected tropical and infectious diseases caused by protozoan organisms such as kinetoplastid
and plasmodium parasites pose a great danger to human lives. Key among these protozoan infections
are the human African trypanosomiasis (HAT), also known as sleeping sickness, caused by two
Trypanosoma brucei subspecies (i.e., Trypanosoma brucei rhodesiense (T. b. rhodesiense) and Trypanosoma
brucie gambiense (T. brucie gambiense)) and malaria caused by five plasmodium species, with Plasmodium
falciparum (P. falciparum) being the most virulent [1–4]. HAT is fatal if left untreated, and T. b. gambiense
accounts for about 95–97% of all cases while T. b. rhodesiense accounts for only 3–5% [5]. In 2018 HAT
and malaria had over 229 million reported cases and 405,000 deaths, the majority being attributed to
the latter [6,7]. However, the number of reported cases and deaths have been dropping significantly
due, in part, to the World Health Organization (WHO) goals of eliminating both HAT and malaria [8,9].
Currently, there are no vaccines against HAT and malaria, even though both have been around
for over a century. There are very few drugs available for treating HAT, and their use depends
on the causative species and the stage, the disease [2,10]. Furthermore, the drawbacks of drugs
such as melarsoprol, pentamidine, suramin and their combinations are the need to be administered
intravenously (IV), toxicity and the ever-present threat of drug resistance emerging [11–14]. Thus, there
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is an urgent need for the development of a pipeline of new drugs against this disease. On the other
hand, resistant forms of the plasmodium parasite are threatening the mainstay of malaria chemotherapy,
artemisinin [15–18]. Therefore, there is also an urgent need for continuously developing newer drugs
that will be efficacious against all forms of the plasmodia parasite.
Previously we reported a series of 4-aminoquinoline- based tetrazole compounds that were more
efficacious, against both the chloroquine (CQ)-sensitive and -resistant strains, than the reference drug
CQ [19,20]. Herein we report a limited and focused number of the second generation of compounds
where the tetrazole moiety is replaced by a β-lactam ring and the 4-amino-7chloroquinoline ring is
replaced by primaquine, an 8-aminoquinoline (Figure 1).
Figure 1. Rationale for the current work.
In the last decade and a half, a number of literature reports have highlighted the use of the
β-lactam moiety in antiprotozoal research, especially as antiplasmodium agents [21–27]. D’hooge et al.
reported a series of nontoxic cis-β-lactams that exhibited IC50 values in the micromolar range against
the CQ-sensitive D10 strain [22] and Singh et al. also reported a series of β-lactams that exhibited
low micromolar potency against three P. falciparum strains (D10, K1 and W2) [23]. On the other hand,
Kumar and coworkers also reported a number of 4-amino-7chloroquinoline-β-lactam hybrids that
possessed antiplasmodium activity in the low micromolar to nanomolar range against the CQ-resistant
W2 strain [24,25]. These hybrids were synthesized by coupling the 4-amino-7chloroquinoline moieties
to separately prepared β-lactams. In our current work, the 4-amino-7chloroquinoline-β-lactam hybrids
are prepared via the Staudinger reaction [22,28], where the 4-amino-7chloroquinoline plays the role
of an amine input in the reaction. Our group also previously reported the antitrypanosomal activity
of gamma- and delta-lactams [29], and to our knowledge, there has not been any literature report of
the evaluation of β-lactam-quinoline hybrids as antitrypanosomal agents. This is in view of the fact
that antimalarial 8-aminoquinolines, i.e., primaquine and tafenoquine, have been reported to show
promising antitrypanosomal activity [30–32].
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2. Results and Discussion
2.1. Chemistry
The synthesis of the 4-amino-7chloroquinoline tethered β-lactams commenced by reacting key
diamines 2a–c [33] with various aromatic aldehydes (1a–e) to give Schiff-bases 3a–g, which were dried
under vacuum prior to use in the next step without any further purification (Scheme 1). The Staudinger
reaction of the Schiff-bases with the methoxy acetyl chloride exclusively furnished the cis β-lactam
products (4a–g) in 4–30% yields and over 90% purity except for 4f that still contained starting Schiff
base traces even after extensive purification. The cis configuration was assigned based on the 1H
NMR model proposed by Xu and coworkers [34,35]. According to the model, when the J-coupling
constant between the two protons on the adjacent chiral carbons of the β-lactam ring is between
4 and 6 ppm, then the configuration is cis, while between 2 and 3 ppm indicates trans. The same
aromatic aldehydes (1a–e) used in β-lactams synthesis were also subjected to the isocyanide-based
Ugi multicomponent reaction involving TMSN3 and commercially available primaquine diphosphate
salt (5) following the method as reported by our group [19,36–38] (Scheme 1). The desired target
compounds (6a–e) were obtained in 21–50% yields as 1:1 diastereomeric mixtures due to the fact that
the primaquine salt used in this study is racemic. Attempts to separate/resolve the diastereomeric
mixture using HPLC was unsuccessful owing to the fact these diastereomeric mixtures coalesce into a
single sharp peak in the HPLC chromatograms (Figures S1–S5) irrespective of whether the gradient of
the mobile phase or pH is varied. Thus, for subsequent biological studies, these 1:1 diastereomeric
mixtures were used without being separated/resolved. All the synthesized target compounds were
fully characterized using routine spectroscopic methods (NMR, IR, MS) (see Table S1 and NMR Figures
in supplementary material) NMR, IR, MS) and their yields and HPLC purities can be found in Table S1
in the supplementary material.
Scheme 1. Reagents and conditions: (i) MeOH, rt, 24 h; (ii) methoxy acetyl chloride, Et3N, DCM, N2,
−78 ◦C (0.5 h), then overnight for 18 h at room temperature; (iii) Primaquine diphosphate salt (4), Et3N,
TMSN3, t-Butyl isocyanide, MeOH, 40 ◦C, 24 h.
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2.2. In Vitro Antiprotozoan Activities
All the synthesized compounds were evaluated in vitro for their antiplasmodium (against
the multidrug K1 resistant strain) and antitrypanosomal activity (against the cultured T. b. brucei
rhodesiense STIB900 parasite strain). Chloroquine, primaquine, melarsoprol and podophyllotoxin were
used as a positive control, and the results are tabulated in Table 1. Generally, all β-lactam based
compounds were more potent than primaquine-based tetrazoles. Furthermore, all the β-Lactam based
compounds also showed superior antiplasmodium activity compared to primaquine, with the most
active 3,4-dichloro substituted 4d (IC50 = 0.20 µM) being 3-fold more active than primaquine and
equipotent to chloroquine. The β-lactam based compounds with the butyl spacer (IC50 = 0.31 µM)
was the most favored compound to the ones with the ethyl (IC50 = 0.47 µM) and propyl spacers
(IC50 = 0.57 µM). None of the primaquine-based tetrazoles had better antiplasmodium activity than
the two reference drugs, with the most active, 3,4-dichloro substituted 6d (IC50 = 1.31 µM), being 2-fold
less active than primaquine and 6-fold less active than chloroquine. In terms of electronic effects,
compounds with an aromatic ring containing moderately electron-withdrawing groups (EWG) (Cl or
diCl) substitutions fared better than those contain electron-donating groups (EDG) (Me and OCH3)
in both sets of compounds. The selective indices of some of the active β-lactam-based compounds
were closer to or greater than 100, indicating that these compounds are more selective towards the
chloroquine-resistant Plasmodium falciparum parasite. Disappointingly, none of these compounds were
as potent as the first-generation compounds against the K1 strain.
Table 1. In vitro antiplasmodium and antitrypanosomal activity, and cytotoxicity of the synthesized
target compounds.






(µM) * SI #
K1 T. b. rhod L6 Cell Lines
4a 1 H H 0.47 53.16 98.47 211
4b 1 OCH3 H 0.62 52.93 20.37 33
4c 1 Me H 0.58 52.54 92.70 160
4d 1 Cl Cl 0.20 18.99 8.54 43
4e 1 Cl H 0.30 7.01 11.52 38
4f 2 H H 0.57 16.09 14.40 25
4 g 3 H H 0.31 20.00 2.87 9
6a - H H 2.47 18.10 10.77 4
6b - OCH3 H 1.98 14.16 75.45 38
6c – CH3 H 1.57 18.54 12.94 8
6d - Cl Cl 1.31 18.30 87.93 67
6e - Cl H 1.80 21.45 31.30 17
Chloroquine - - - 0.22 - - -
Primaquine - - - 0.64 - - -
Melarsoprol - - - 0.0075 - -
Podophyllotoxin - - - - 0.0193 -
* All IC50; # Selectivity Indices (SI) [(IC50 L6 Cell Line)/(IC50 K1 strain)].
Against T. b. brucei rhodesiense, all the tested compounds showed moderate activity, and none
of them had superior activity than the reference drug, melarsoprol. Compounds 4e (IC50 = 7.01 µM)
and 6b (IC50 = 14.16 µM) were the most active in the β-lactam and tetrazole series, respectively.
Unlike in the case of activity against Plasmodium falciparum, the compound with the propyl spacer
(IC50 = 16.09 µM) was more active than compounds with ethyl (IC50 = 53.16 µM) and butyl spacers
(IC50 = 20.00 µM). In terms of electronic effects, compounds containing EWG in the β-lactam series
were more active than those containing EDG. However, in the tetrazole series, no electronic effect trend
could be delineated since all the compounds had comparable activities.
2.3. Solubility of Selected Compounds
A limited number of compounds from each series were selected for assessment of their aqueous
kinetic solubility at pH 7.0:4a, 4e and 4g from the β-lactam series and 6c–e from the tetrazole series
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(Table 2). These compounds were selected based on their good antiplasmodium (4a, 4e and 4g),
promising antitrypanosomal (4d and 6c–e) and excellent cytotoxicity (4a and 6d) profiles. The β-lactam
series of compounds generally exhibited excellent solubility (>200 µM) compared to the tetrazole series
compounds (<20 µM).
Table 2. Aqueous kinetic solubility of selected compounds.







3. Materials and Methods
3.1. General Information
All chemical reagents used were supplied by either Sigma-Aldrich® (Johannesburg, South Africa)
or Merck (Johannesburg, South Africa) and were used without further purification. Unless otherwise
stated, all the solvents used were anhydrous and were purchased from Sigma-Aldrich, with the
exception of THF and diethyl ether, which were dried in-house prior to use. Chromatographic
solvents such as Ethyl acetate, dichloromethane and Hexane were purchased from Kimix (Cape Town,
South Africa) or Protea Chemicals (Cape Town, South Africa) and were distilled prior to use.
HPLC grade methanol, acetonitrile and formic acid (98–100%) were purchased from Sigma-Aldrich.
Ultrafiltered water was purified by a Millipore Synergy water purification system (Microsep, Tygervalley,
South Africa) and was used as such. The progress of the reactions was monitored by thin-layer
chromatography (TLC) using Merck PF254 aluminum-backed precoated silica gel plates and viewed
under ultraviolet (UV) light, and where necessary, visualized using iodine vapor. Product purification on
the flash column chromatography was carried out using Merck Kieselgel 60:70–230 mesh. Both analytical
and preparative HPLC were performed on a modular Waters HPLC system consisting of a 2767 sample
manager, 2545 quaternary gradient pump, 1500 series column heater and a 2998 photodiode array
detector (PDA) with a Prep 2998 flow-cell. Waters Xbridge C18, 4.6 × 150 mm column with 5 µm
particles was used for the analytical scale HPLC analysis and a Waters Xbridge C18, OBD 19 × 250 mm
preparative HPLC column was used for the purifications. Xbridge C18, 5 µm, 4.6 × 20 mm and Xbridge
C18, 5 µm, 19 × 10 mm guard columns were connected to the inlets of the analytical and preparative
HPLC columns, respectively (Microsep, Tygervalley, South Africa).
Melting points were determined on a Reichert-Jung Thermovar hot-stage microscope and are
uncorrected. Mass spectra were obtained by flow-injection (5 mM NH4 formate pH 3 in H2O:ACN,
no column used) on an AB SCIEX 4000 QTRAP Hybrid triple quadrupole linear ion trap mass
spectrometer, coupled with an Agilent 1200 Rapid Resolution (600 bar) HPLC system consisting of
a binary pump, degasser, autosampler and temperature-controlled column compartment (SCIEX,
Johannesburg, South Africa). Infra-red spectra were recorded on a PerkinElmer Spectrum 100 FT-IR
spectrometer (Perkin Elmer SA, Midrand, South Africa) in the 4000–450 cm−1 range, with samples
dissolved in dichloromethane solution or placed in KBr discs. NMR spectra were recorded on Bruker
400 MHz (Bruker, Bremen, Germany) and/or Varian Unity 400 MHz and/or Varian Mercury 300 MHz
spectrometers (Agilent Technologies, CA, USA). All chemical shifts are reported in ppm and were
referenced using solvent signals (2.50 and 39.4 ppm for DMSO-d6 and 7.6 and 77.0 ppm for CDCl3).
Chemical shifts (δ) are recorded in parts per million (ppm). Coupling constants, J, are measured in
Hertz (Hz) and rounded off to one decimal place. Abbreviations used in the assignment of the 1H NMR
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spectra are as follows: br (broad), d (doublet), dd (doublet of doublets), m (multiplets), s (singlet) and t
(triplet). 13C NMR chemical shifts are listed without assignment to specific carbon atoms.
3.2. Synthetic Procedures
3.2.1. General Procedure for the β-Lactam Based Compounds
Quinoline diamine 2a–c (1.0 mmol) and various aldehydes 1a–e (1.0 mmol) were stirred in
anhydrous methanol at room temperature for 24 h to afford Schiff-based 3a–g that were subsequently
used, after drying in vacuum for 4 h, in the next step without any further purification. Dry DCM
(5 mL), followed by Et3N (3.0 eq), was added to the Schiff-based (1.0 eq), and the resulting mixtures
were stirred for 30 min at −78 ◦C under an inert N2 atmosphere. Thereafter, methoxy acetyl chloride
(1.5 eq) in dry DCM (2 mL) was added to the mixtures dropwise, mixtures allowed to warm to room
temperature and further stirred overnight for 18 h at room temperature. On completion, saturated
NaHCO3 was then added to the mixtures and the organic layers extracted with DCM. The combined
organic extracts were then washed with brine and water, dried over anhydrous MgSO4 and solvent
removed in vacuo to yield crude products, which were purified by column chromatography to
exclusively give the cis β-lactam based compounds:
1-[2-(7-Chloroquinolin-4-ylamino)ethyl]-3-methoxy-4-phenylazetidin-2-one 4a, as a white solid (55 mg, 30%);
m. p. 142–146 ◦C, Rf (DCM: MeOH, 95: 0.5%) 0.21; IR νmax (DCM)/cm−1 1744 (C = O), 1620 (Ar C = C),
1264 (C-O ester); δH (400 MHz; CDCl3) 8.49 (1H, d, J 5.4 Hz, H2), 8.00 (1H, d, J 2.1 Hz, H8), 7.84 (1H, d,
J 9.0 Hz, H5), 7.42 (1H, dd, J 9.0 and 2.1 Hz, H6), 7.35 (5H, m, ArH), 6.26 (1H, d, J 5.4 Hz, H3), 4.97 (1H,
d, J 4.4 Hz, H1′), 4.74 (1H, d, J 4.4 Hz, H2′), 3.54 (2H, m, H9), 3.46 (2H, m, H10), 3.12 (3H, s, H6′); δC
(101 MHz; CDCl3) 168.9, 151.5, 149.8, 148.8, 135.3, 133.2, 129.1, 128.7 (2C), 128.4, 128.3 (2C), 125.8, 121.9,
117.3, 98.5, 85.4, 63.3, 58.2, 42.4 and 41.1; LCMS m/z 382 [M + H]+, HPLC purity: 95.6%; tr’ = 8.37 min.
1-[2-(7-Chloroquinolin-4-ylamino)ethyl]-3-methoxy-4-(4-methoxyphenyl)azetidin-2-one 4b, as a yellow solid
(44.6 mg, 9%); m. p. 144–147 ◦C, Rf (DCM: MeOH, 95: 0.5%) 0.21; IR νmax (DCM)/cm−1 1746 (C = O),
1610 (Ar C = C), 1267 (C-O ester); δH (400 MHz; CDCl3) 8.48 (1H, d, J 5.5 Hz, H2), 7.98 (1H, s, H8), 7.84
(1H, d, J 8.9 Hz, H5), 7.41 (1H, d, J 9.0, H6), 7.24 (2H, d, J 8.6 Hz, 2 ×H4′), 6.86 (2H, d, J 8.6 Hz, 2 ×H3′),
6.45 (1H, br s, NH), 6.25 (1H, d, J 5.5 Hz, H3), 4.74 (1H, d, J 4.4 Hz, H1′), 4.71 (1H, d, J 4.4 Hz, H2′), 3.79
(3H, s, H5′), 3.52 (2H, t, J 4.6 Hz, H9), 3.47 (1H, m, H10a), 3.41 (1H, m, H10b), 2.92 (3H, s, H6′); δC
(101 MHz; CDCl3) 169.0, 160.3, 151.1, 150.1, 148.3, 135.5, 129.7 (2C), 127.9, 125.9, 124.8, 122.0, 117.2, 114.1
(2C), 98.4, 85.3, 62.9, 58.2, 55.3, 42.5 and 40.9; LCMS m/z 412 [M + H]+, HPLC purity: 95.6%; tr’ = 8.43 min.
1-[2-(7-Chloroquinolin-4-ylamino)ethyl]-3-methoxy-4-p-tolylazetidin-2-one 4c, as a yellow solid (21 mg,
6%); m. p. 78–82 ◦C, Rf (DCM: MeOH, 95: 0.5%) 0.31; IR νmax (DCM)/cm−1 1744 (C = O), 1604 (Ar
C = C), 12,652 (C-O ester); δH (400 MHz; CDCl3) 8.49 (1H, d, J 1.3 Hz, H8), 8.04 (1H, d, J 5.7 Hz, H2),
7.88 (1H, d, J 9.0 Hz, H5), 7.41 (1H, dd, J 9.0 and 1.3 Hz, H6), 7.20 (2H, d, J 8.0 Hz, 2 ×H4′), 7.14 (2H,
d, J 8.0 Hz, 2 × H3′), 6.78 (1H, br s, NH), 6.24 (1H, d, J 5.7 Hz, H3), 4.77 (1H, d, J 4.3 Hz, H1′), 4.73
(1H, d, J 4.3 Hz, H2′), 3.52 (2H, m, H9), 3.47 (2H, m, H10), 3.13 (3H, s, H6′), 2.35 (3H, s, H5′); δC
(101 MHz; CDCl3) 169.0, 150.7, 150.1, 147.1, 139.1, 136.0, 129.4 (2C), 128.9, 128.4 (2C), 126.8, 126.1, 122.3,
117.0, 98.2, 85.3, 63.1, 58.2, 42.5, 40.9 and 21.6; LCMS m/z 396 [M + H]+, HPLC purity: 94.6%; tr’ = 8.29 min.
1-[2-(7-Chloroquinolin-4-ylamino)ethyl]-4-(3,4-dichlorophenyl)-3-methoxyazetidin-2-one 4d, as a pale-yellow
solid (17.3 g, 4%); m. p. 152–156 ◦C, Rf (DCM: MeOH, 95: 0.5%) 0.16; IR νmax (DCM)/cm−1 1739
(C = O), 1601 (Ar C = C), 1277 (C-O ester); δH (400 MHz; CDCl3) 8.45 (1H, d, J 5.6 Hz, H2), 7.96 (1H, d,
J 2.1 Hz, H8), 7.89 (1H, d, J 9.0 Hz, H5), 7.39 (3H, m, ArH), 7.16 (1H, dd, J 9.0 and 2.1 Hz, H6), 6.74 (1H,
br s, NH), 6.25 (1H, d, J 5.6 Hz, H3), 4.78 (1H, d, J 4.4 Hz, H1′), 4.74 (1H, d, J 4.4 Hz, H2′), 3.49 (2H, m,
H9), 3.43 (2H, m, H10), 3.18 (3H, s, H6′); δC (101 MHz; CDCl3) 168.6, 150.5, 150.1, 147.2, 136.0, 133.7,
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133.2, 130.6, 130.4, 127.6, 127.0, 126.2, 126.1, 122.2, 117.0, 98.3, 85.5, 62.1, 58.6, 42.2 and 41.0; LCMS m/z
450 [M + H]+, HPLC purity: 99.5%; tr’ = 8.81 min.
1-[2-(7-Chloroquinolin-4-ylamino)ethyl]-4-(4-chlorophenyl)-3-methoxyazetidin-2-one 4e, as a pale-yellow
solid (20.3 mg, 14%); m. p. 135–138 ◦C, Rf (DCM: MeOH, 95: 0.5%) 0.14; IR νmax (DCM)/cm−1 1740
(C = O), 1598 (Ar C = C), 1265 (C-O ester); δH (400 MHz; CDCl3) 8.46 (1H, d, J 5.3 Hz, H2), 7.95 (1H, d, J
1.9 Hz, H8), 7.85 (1H, d, J 9.0 Hz, H5), 7.39 (1H, dd, J 9.0 and 1.9 Hz, H6), 7.31 (2H, d, J 8.5 Hz, 2 × H4′),
7.24 (2H, d, J 8.5 Hz, 2 × H3′), 6.47 (1H, br s, NH), 6.24 (1H, d, J 5.3 Hz, H3), 4.77 (1H, d, J 4.3 Hz,
H1′), 4.72 (1H, d, J 4.3 Hz, H2′), 3.54 (1H, m, H10a), 3.47 (3H, m, H9 and H10b), 3.13 (3H, s, H6′); δC
(101 MHz; CDCl3) 168.7, 151.2, 150.0, 148.4, 135.4, 135.1, 131.2, 129.7 (2C), 128.9 (2C), 128.0, 125.9, 122.0,
117.2, 98.5, 85.4, 62.6, 58.3, 42.3 and 41.0; LCMS m/z 416 [M + H]+, HPLC purity: 99.2%; tr’ = 8.63 min.
1-[3-(7-Chloroquinolin-4-ylamino)propyl]-3-methoxy-4-phenylazetidin-2-one 4f, as a yellow paste (19.6 mg,
5%); Rf (DCM: MeOH, 95: 0.5%) 0.41; IR νmax (DCM)/cm−1 1745 (C = O), 1609 (Ar C = C), 1269 (C-O
ester); δH (300 MHz; CDCl3) 8.59 (1H, d, J 5.4 Hz, H2), 8.11–8.13 (2H, m, H5 and H8), 7.99 (1H, d, J 9.0
Hz, H6), 7.47–7.52 (5H, m, ArH), 6.51 (1H, br s, NH), 6.46 (1H, d, J 5.4 Hz, H3), 4.85 (1H, d, J 4.4 Hz,
H1′), 4.81 (1H, d, J 4.4 Hz, H2′), 3.60 (3H, s, H6′), 3.49 (2H, m, H11), 3.28 (2H, m, H9), 1.97 (2H, m, H10;
δC (75 MHz; CDCl3) 169.2, 155.2, 147.5, 140.1, 136.8, 136.2, 129.0, 128.7, 128.5, 128.1, 126.6, 125.9, 124.3,
122.1, 117.5, 98.5, 85.1, 61.9, 57.8, 42.1, 40.5 and 26.7; LCMS m/z 397 [M + H]+.
1-[4-(7-Chloroquinolin-4-ylamino)butyl]-3-methoxy-4-phenylazetidin-2-one 4g, as a yellow solid (28 mg, 9%);
m. p. 86–89 ◦C, Rf (DCM: MeOH, 95: 0.5%) 0.31; IR νmax (DCM)/cm−1 1739 (C = O), 1599 (Ar C = C),
1258 (C-O ester); δH (400 MHz; CDCl3) 8.39 (1H, d, J 9.0 Hz, H5), 8.28 (1H, d, J 5.6 Hz, H2), 8.05 (1H, s,
H8), 7.92 (1H, br s, NH), 7.36 (6H, m, H6 and ArH), 6.39 (1H, d, J 5.6 Hz, H3), 4.76 (1H, d, J 4.3 Hz,
H1′), 4.73 (1H, d, J 4.3 Hz, H2′), 3.44 (4H, m, H9 and H12), 3.09 (3H, s, H6′), 1.92 (2H, m, H10), 1.72 (2H,
m, H11); δC (101 MHz; CDCl3) 167.7, 153.5, 145.6, 142.7, 137.7, 133.5, 128.8, 128.5 (2C), 128.4, 126.7,
126.2, 124.1, 123.1, 116.3, 98.1, 85.4, 62.4, 58.1, 43.2, 40.9, 25.6 and 25.1; LCMS m/z 411 [M + H]+, HPLC
purity: 98.0%; tr’ = 9.12 min.
3.2.2. General Procedure for the Tetrazole-Based Compounds
The procedure reported previously by Tukulula et al. [19,36–38] was followed. Briefly,
the commercially available racemic primaquine diphosphate salt 4 (1.1 mmol) was reacted, in Ugi
multicomponent reaction conditions, with aromatic aldehydes 1a–e (1.1 mmol), TMSN3 (1.1 mmol)
and tert-butyl isocyanide (1.1 mmol) in the presence of triethylamine (4.0 eq) at 40 ◦C for 24 h to
afford crude desired compounds as unresolved racemic 1:1 diastereomeric mixtures 6a–e. These the
diastereomeric mixtures were then purified by both column chromatography and by HPLC with no
success in resolving/separating them:
N-{5-[(1-tert-butyl-1H-tetrazol-5-yl)(phenyl)methylamino]pentan-2-yl}-6-methoxyquinolin-8-amine 6a, as
a thick yellow oil (108.4 mg, 21%); Rf (DCM: acetone, 95: 05%) 0.50; IR νmax (DCM)/cm−1 1615 (Ar
C = C), 1385 (N = N), 1315 (C = N), 1266 (C-N), 1254 (C-O ester); δH (300 MHz; CDCl3) 8.47 (1H, m,
H2), 7.88 (1H, dd, J 8.3 and 1.6 Hz, H4), 7.25 (6H, m, ArH and H3), 6.29 (1H, d, J 2.3 Hz, H7), 6.23 (1H,
d, J 2.5 Hz, H5), 5.99 (1H, t, J 8.6 Hz, NH), 5.22 (1H, d, J 6.7 Hz, H14), 3.85 (3H, s, OCH3), 3.56 (1H, m,
H9), 2.53 (2H, m, H13), 1.63 (4H, m, H11 and H12), 1.55 (9H, d, J 4.04 Hz, 3 ×H18), 1.25 (3H, d, J 6.4 Hz,
H10); δC (75 MHz; CDCl3) 159.5, 155.7, 145.0, 144.2, 138.9, 135.4, 134.7, 129.9, 128.9 (2C), 128.2, 128.0
(2C), 121.8, 96.6, 91.6, 61.2, 59.0, 55.2, 55.1, 47.9, 34.2, 30.0 (3C), 26.5 and 20.5; LCMS m/z 474 [M + H]+;
HPLC purity: 99.3%; tr’ = 16.53 min.
N-{5-[(1-tert-butyl-1H-tetrazol-5-yl)(methoxyphenyl)methylamino]pentan-2-yl}-6-methoxyquinolin-8-
amine 6b, as a yellow oil (219.6 mg, 40%); Rf (DCM: acetone, 95: 05%) 0.54; IR νmax (DCM)/cm−1 1615
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(Ar C = C), 1387 (N = N), 1269 (C = N), 1266 (C-N), 1217 (C-O ester); δH (400 MHz; CDCl3) 8.50 (1H, m,
H2), 7.91 (1H, dd, J 8.3 and 1.8 Hz, H4), 7.29 (1H, dd, J 8.2 and 4.2 Hz, H3), 7.18 (2H, m, 2×H16), 6.83 (2H,
m, 2 ×H15), 6.32 (1H, d, J 1.7 Hz, H7), 6.26 (1H, d, J 1.7 Hz, H5), 6.03 (1H, m, NH), 5.20 (1H, d, J 9.0 Hz,
H14), 3.85 (3H, d, J 1.4 Hz, OCH3), 3.77 (3H, d, J 1.0 Hz, H17), 3.61 (1H, m, H9), 2.54 (2H, m, H13), 1.67 (4H,
m, H11 and H12), 1.57 (9H, d, J 5.3 Hz, 3 ×H18), 1.28 (3H, d, J 6.4 Hz, H10); δC (101 MHz; CDCl3) 159.4,
155.9, 145.1, 144.2 (2C), 135.4, 134.7 (2C), 131.0, 129.9, 129.2 (2C), 121.8, 114.3 (2C), 96.6, 91.6, 61.1, 58.3,
55.2, 47.9 (2C), 34.2, 30.0 (3C), 26.5 and 20.5; LCMS m/z 505 [M + H]+; HPLC purity: 99.5%; tr’ = 16.39 min.
N-{5-[(1-tert-butyl-1H-tetrazol-5-yl)(p-tolyl)methylamino]pentan-2-yl}-6-methoxyquinolin-8-amine 6c, as a
thick yellow oil (265.9 mg, 50%); Rf (DCM: acetone, 95: 05%) 0.51; IR νmax (DCM)/cm−1 1617 (Ar C = C),
1390 (N = N), 1325 (C = N), 1260 (C-N), 1232 (C-O ester); δH (400 MHz; CDCl3) 8.53 (1H, m, H2), 7.93
(1H, dd, J 8.3 and 1.7 Hz, H4), 7.31 (1H, dd, J 8.3 and 4.2 Hz, H3), 7.12–7.18 (4H, m, 2 ×H16 and 2 ×
H15), 6.34 (1H, d, J 2.4 Hz, H7), 6.28 (1H, d, J 2.5 Hz, H5), 6.04 (1H, m, NH), 5.29 (1H, d, J 8.2 Hz,
H14), 3.91 (3H, d, J 1.3 Hz, OCH3), 3.62 (1H, m, H9), 2.57 (2H, m, H13), 2.33 (3H, s, H17), 1.69 (4H, m,
H11 and H12), 1.60 (9H, d, J 5.4 Hz, 3 ×H18), 1.25 (3H, d, J 6.4 Hz, H10); δC (101 MHz; CDCl3) 159.5,
155.9, 145.1, 144.2 (2C), 138.0, 135.9, 135.2, 134.7, 129.9, 129.6 (2C), 127.9 (2C), 121.8, 96.6, 91.6, 61.2, 58.7,
55.2, 47.9, 34.2, 30.1 (3C), 26.5, 21.0 and 20.5; LCMS m/z 488 [M + H]+; HPLC purity: 99.4%; tr’ = 16.99 min.
N-{5-[(1-tert-butyl-1H-tetrazol-5-yl)(3,4-dichlorophenyl)methylamino]pentan-2-yl}-6-methoxyquinolin-8-
amine 6d, as a thick yellow oil (100.5 mg, 17%); Rf (DCM: acetone, 95: 0.5%) 0.29; IR νmax (DCM)/cm−1
1609 (Ar C = C), 1383 (N = N), 1330 (C = N), 1264 (C-N), 1245 (C-O ester); δH (400 MHz; CDCl3) 8.53
(1H, m, H2), 7.94 (1H, dd, J 8.3 and 1.6 Hz, H4), 7.42 (1H, d, J 2.1 Hz, H15), 7.42 (1H, d, J 2.1 Hz, H16),
7.38 (1H, s, H17), 7.32 (1H, dd, J 8.2 and 4.2 Hz, H3), 6.35 (1H, d, J 1.9 Hz, H7), 6.28 (1H, d, J 2.2 Hz, H5),
6.03 (1H, m, NH), 5.22 (1H, d, J 9.6 Hz, H14), 3.91 (3H, d, J 1.4 Hz, OCH3), 3.62 (1H, m, H9), 2.56 (2H,
m, H13), 1.69 (4H, m, H11 and H12), 1.63 (9H, d, J 12.1 Hz, 3 × H18), 1.25 (3H, d, J 6.4 Hz, H10); δC
(101 MHz; CDCl3) 159.5, 155.0, 145.0, 144.3, 139.1, 135.4, 134.7, 132.6, 130.8, 130.1, 130.0, 129.9, 127.3,
121.8, 96.6, 91.6, 61.3, 57.8, 55.2, 47.9, 34.0, 33.7, 30.0 (3C), 26.5 and 20.8; LCMS m/z 542.0 [M + H]+;
HPLC purity: 99.5%; tr’ = 18.28 min.
N-{5-[(1-tert-butyl-1H-tetrazol-5-yl)(4-chlorophenyl)methylamino]pentan-2-yl}-6-methoxyquinolin-8-
amine 6e, as a thick yellow oil (228.5 mg, 41%); Rf (DCM: acetone, 95: 0.5%) 0.52; IR νmax (DCM)/cm−1
1630 (Ar C = C), 1380 (N = N), 1335 (C = N), 1278 (C-N), 1246 (C-O ester);δH (400 MHz; CDCl3) 8.52
(1H, dd, J 4.2 and 1.6 Hz, H2), 7.93 (1H, dd, J 8.4 and 1.6 Hz, H4), 7.26–7.42 (5H, m, ArH and H3), 7.35
(1H, d, J 2.4 Hz, H7), 6.28 (1H, d, J 2.4 Hz, H5), 6.03 (1H, m, NH), 5.24 (1H, d, J 12.0 Hz, H14), 3.90 (3H,
d, J 2.2 Hz, OCH3), 3.63 (1H, m, H9), 2.55 (2H, m, H13), 1.68 (4H, m, H11 and H12), 1.60 (9H, d, J 6.1
Hz, 3 × H17), 1.30 (3H, d, J 6.4 Hz, H10); δC (101 MHz; CDCl3) 159.5, 155.4, 145.0, 144.2 (2C), 137.4,
135.4, 134.7, 134.2, 129.9, 129.4 (2C), 129.1 (2C), 121.8, 96.6, 91.6, 61.3, 58.2, 55.2, 47.8, 34.1, 30.0 (3C), 26.5
and 20.6; LCMS m/z 508 [M + H]+; HPLC purity: 99.7%; tr’ = 17.25 min.
3.3. In Vitro Biological Evaluations
Antiplasmodial activity on the K1 strain, antitrypanosomal activity on T. b. brucei rhodesiense
STIB900 and cytotoxicity on the L6 mammalian cell-line were all carried out at the Swiss Tropical and
Public Health Institute (STPH), Switzerland as follows:
3.3.1. Activity Against K1 Strain of P. falciparum
In vitro activity against erythrocytic stages of P. falciparum was determined using a
3H-hypoxanthine incorporation assay, using the chloroquine and pyrimethamine-resistant K1 strain
that originates from Thailand and the standard drug chloroquine (Sigma C6628) [39–41]. Compounds
were dissolved in DMSO at 10 mg/mL and added to parasite cultures incubated in RPMI 1640 medium
without hypoxanthine, supplemented with HEPES (5.94 g/L), NaHCO3 (2.1 g/L), neomycin (100 U/mL),
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AlbumaxR (5 g/L) and washed human red cells A+ at 2.5% hematocrit (0.3% parasitemia). Serial
drug dilutions of eleven three-fold dilution steps covering a range from 100 to 0.002 µg/mL were
prepared. The 96-well plates were incubated in a humidified atmosphere at 37 ◦C; 4% CO2, 3% O2,
93% N2. After 48 h, 50 µL of 3H-hypoxanthine (= 0.5 µCi) was added to each well of the plate. The test
compounds were tested in triplicate ad parasite growth compared to control or blank well. The plates
were incubated for a further 24 h under the same conditions. The plates were then harvested with
a Betaplate™ cell harvester (Wallac, Zurich, Switzerland), and the red blood cells transferred onto a
glass fiber filter then washed with distilled water. The dried filters were inserted into a plastic foil with
10 mL of scintillation fluid and counted in a Betaplate™ liquid scintillation counter (Wallac, Zurich,
Switzerland). IC50 values were calculated from sigmoidal inhibition curves by linear regression using
Microsoft Excel.
3.3.2. Activity against Trypanosoma brucei rhodesiense STIB900
This stock was isolated in 1982 from a human patient in Tanzania and, after several mouse
passages, was cloned and adapted to axenic culture conditions [41–43]. Minimum essential medium
(50 µL) supplemented with 25 mM HEPES, 1 g/L additional glucose, 1% MEM non-essential amino
acids (100×), 0.2 mM 2-mercaptoethanol, 1 mM Na-pyruvate and 15% heat-inactivated horse serum
was added to each well of a 96-well microtiter plate. Serial drug dilutions of eleven three-fold dilution
steps covering a range from 100 to 0.002 µg/mL were prepared. Then, 4 × 103 bloodstream forms of
T. b. rhodesiense STIB 900 in 50 µL was added to each well and the plate incubated at 37 ◦C under a
5% CO2 atmosphere for 70 h. 10 µL alamarBlue (resazurin, 12.5 mg in 100 mL double-distilled water)
was then added to each well and incubation continued for a further 2–4 h. Then the plates were read
with a Spectramax Gemini XS microplate fluorometer (Molecular Devices Cooperation, Sunnyvale,
CA, USA) using an excitation wavelength of 536 nm and an emission wavelength of 588 nm. The test
compounds were tested in triplicate, and their IC50 values were calculated by linear regression from
the sigmoidal dose inhibition curves using Softmax Pro software (Molecular Devices Cooperation,
Sunnyvale, CA, USA).
3.3.3. In Vitro Cytotoxicity with L-6 Cells
Assays were performed in triplicate in 96-well microtiter plates, each well containing 100 µL
of RPMI 1640 medium supplemented with 1% L-glutamine (200 mM) and 10% fetal bovine serum,
and 4000 L-6 cells (a primary cell line derived from rat skeletal myoblasts) [41,44,45]. Serial drug
dilutions of eleven three-fold dilution steps covering a range from 100 to 0.002 µg/mL were prepared.
After 70 h of incubation, the plates were inspected under an inverted microscope to assure the growth
of the controls and sterile conditions. 10 µL of alamarBlue was then added to each well, and the
plates incubated for another 2 h. Then the plates were read with a Spectramax Gemini XS microplate
fluorometer (Molecular Devices Cooperation, Sunnyvale, CA, USA) using an excitation wavelength of
536 nm and an emission wavelength of 588 nm. The IC50 values were calculated by linear regression
from the sigmoidal dose inhibition curves using Softmax Pro software (Molecular Devices Cooperation,
Sunnyvale, CA, USA).
3.3.4. Aqueous Kinetic Solubility
A 10 mM stock of the compound was diluted in DMSO to give standard solutions at 220 µM,
100 µM and 10 µM in a 96 well plate as described previously [19]. The 10 mM stock was then spiked
1:50 in phosphate-buffered saline pH 7.0 to give a final DMSO concentration of 2%. Both the standard
and sample solutions were plated in triplicate. After shaking for 2 h at 25 ◦C, the solutions were
filtered and analyzed on an Agilent 1200 series HPLC with DAD detection. The solubility of the
test compounds was determined by comparing the peak area of the sample solutions to that of the
standard solutions.
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4. Conclusions
In this study, we presented the synthesis of 4-amino-7chloroquinoline tethered β-lactams
and primaquine-based tetrazoles, the latter obtained as unresolved 1:1 diastereomeric mixtures.
The configuration of the β-lactams was assigned as cis based on the NMR analysis. The in vitro
antiplasmodium activity of all the β-lactams was superior to those of the primaquine-based tetrazoles
and primaquine reference drug, with compounds 4d–e and 4g being two to three-fold more active
than primaquine while 4d was also equipotent to chloroquine. The most active compound in the
tetrazole series, 6d, was 2- and 6-fold less active than primaquine and chloroquine, respectively.
The antitrypanosomal activity of all the synthesized compounds was moderate, with compounds
4d, 4e–g and 6a–d displaying encouraging antitrypanosomal activities less than 20 µM. Furthermore,
three β-lactams and three tetrazoles were assessed for their aqueous kinetic solubility and generally,
the β-lactams compounds exhibited superior solubility (>200 µM) compared to those of tetrazoles
(<20 µM).
Supplementary Materials: The following are available online. Table S1: Yields and HPLC purity of the synthesized
compounds; preparative and analytical HPLC methods, HPLC chromatograms for 1:1 diastereomeric mixtures
(Figures S1–S5), 1H and 13C NMR spectra of the synthesized target compounds.
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